Drug intelligence / Profile preview

RG-OVV01

Development stage: Preclinical
Lead developer: Shanghai Rongrui Pharmaceutical
Modality: Oncolytic Viruses → Oncolytic Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intratumoral, Intravenous

Overview

RG-OVV01 is an investigational, preclinical-stage chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Hangzhou RonGu Biotechnology for the treatment of solid tumors. The therapeutic candidate is engineered using lentiviral gene transfer and incorporates an oncolytic virus (OVV) component to enhance anti-tumor efficacy. The specific molecular targets of the CAR-NK and the oncolytic virus have not been publicly disclosed.

Targets

NY-ESO-1 (New york esophageal squamous cell carcinoma 1)

Beyond the preview

Go deeper on RG-OVV01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG-OVV01.

Explore the full profile